Greenland Capital Management LP Takes $3.84 Million Position in Kenvue Inc. $KVUE

Greenland Capital Management LP bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 201,087 shares of the company’s stock, valued at approximately $3,843,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Physician Wealth Advisors Inc. raised its stake in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Kenvue in the 4th quarter valued at $26,000. Johnson Financial Group Inc. acquired a new stake in Kenvue during the 2nd quarter worth $26,000. MV Capital Management Inc. acquired a new stake in Kenvue during the 4th quarter worth $28,000. Finally, CoreCap Advisors LLC grew its holdings in shares of Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.2%

Shares of Kenvue stock opened at $18.82 on Wednesday. The stock has a 50 day moving average of $19.00 and a 200 day moving average of $18.16. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The firm has a market capitalization of $36.15 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.84.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. During the same quarter in the prior year, the firm earned $0.29 EPS. Kenvue’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a $0.21 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.5%. Kenvue’s payout ratio is presently 96.55%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KVUE shares. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.